Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Stopped early · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin

Key facts

Study ID

NCT01068756

Run by

AstraZeneca

People needed

14

Starts

2010-03-01

Expected to finish

2010-04-01

Last updated by the study team

2016-10-17

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects
• Body Mass Index (BMI) of 18 to 32 inclusive
• Women who are not of childbearing potential and men, ages 18 to 45

You may not qualify if…

• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiogram (ECG) or clinical laboratory determinations
• Glucosuria
• Abnormal liver function tests

Where it is running

• Ppd Development — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.